ASCO and NCCN have released guidelines on assessment and management of immune checkpoint inhibitor–related side effects.
Mark L. Fuerst
Coffee may soon contain a warning that it contains acrylamide, a known carcinogen. A recent lawsuit filed by the nonprofit Council for Education and Research in Toxics alleges that coffee shops in California “failed to provide clear and reasonable warning” that their product could expose people to acrylamide.
Typical cell phone use is unlikely to cause cancer via radiation exposure, according to government researchers.
Nearly two-thirds of older patients with stage III lung cancer do not receive any treatment, according to a new study.
Acalabrutinib continues to yield high response rates in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies.
A combination of the FLT3 kinase inhibitor quizartinib with 5-azacitidine or low-dose cytarabine is active in patients with FLT3-ITD mutated myeloid leukemias, according to a new study.
A combination of ibrutinib plus standard chemoimmunotherapy induces deep responses in a relatively high-risk group of previously untreated, young chronic lymphocytic leukemia patients, according to a new study.
A precision medicine clinical trial based on genomic abnormalities has screened nearly 6,000 patients in just under 2 years and matched 18% of tumors screened with a genetic mutation to one of 30 treatment arms.
An increase in the number of approved cancer therapeutics has led to an associated increase in early-phase trials that have adopted a seamless approach.